The pharmaceutical equipment industry still maintained a growth trend in the first quarter, and many companies achieved a "good start"

[Pharmaceutical Network Industry News] As of now, most pharmaceutical machine companies have basically announced their performance in 2021 and the first quarter of 2022
.

In 2021, under the background of strong demand in the downstream pharmaceutical industry, domestic pharmaceutical machine companies ushered in an increase in orders.
At the same time, some domestic equipment, with the advantages of high cost performance, fast delivery, and timely after-sales service, seized the huge domestic substitution and export overseas.
Opportunities, the overall performance of the pharmaceutical equipment industry in 2021 is dazzling
.

Entering 2022, judging from the situation of companies that have disclosed their performance in the first quarter, the pharmaceutical machine industry will still maintain a growth trend
.

 Pharmaceutical Equipment (Source: Pharmaceutical Network) In the first quarter, many companies achieved a "good start".
Among the pharmaceutical machine companies that have disclosed their transcripts for the first quarter of 2022, the leading companies represented by Chutian Technology and Tofflon have achieved A "good start"
.

Among them, Chutian Technology’s first-quarter results announcement released on the evening of April 26 showed that the revenue in the first quarter of 2022 was about 1.
369 billion yuan, a year-on-year increase of 20.
14%; the net profit was about 128 million yuan, a year-on-year increase of 22.
05%
.

 　　Tofflon released its 2022 first quarter report on the evening of April 29.
In the first quarter of this year, the company achieved operating income of 1.
237 billion yuan, a year-on-year increase of 72.
67%; net profit attributable to shareholders of the listed company was 211 million yuan, a year-on-year increase of 91.
44%
.

 　　In addition, Canaan Technology disclosed the first quarter report of 2022 on April 28
.

During the reporting period, the company achieved operating income of 210 million yuan, a year-on-year increase of 25.
13%; net profit attributable to the parent was 18.
0942 million yuan, a year-on-year increase of 68.
21%
.

 　　Regarding the reasons for the substantial increase in revenue, Tofflon mentioned in the report that in order to meet the needs of customers, actively tap potentials and improve delivery capabilities, the company's main products include injection stand-alone machines and systems, biological engineering stand-alone machines and systems, medical equipment and Consumables, purification equipment and engineering, API units and systems, inspection and packaging units and systems, solid preparation units and systems, as well as after-sales services and accessories have increased significantly
.

 　　The future development trend of the industry In the context of strong downstream demand and accelerated localization of equipment, the pharmaceutical equipment industry has ushered in a new round of development opportunities
.

At the same time, with the rapid development of biological drugs and innovative drugs in China, many pharmaceutical companies are actively exploring overseas markets, and the requirements for pharmaceutical equipment have also been further improved.
It is expected that the future competition pattern of the pharmaceutical equipment industry will improve
.

 　　Looking forward to the future, the industry believes that automation, intelligence, high performance, high reliability, energy saving and emission reduction will be the future development trends of the pharmaceutical equipment industry
.

 　　Among them, in terms of performance and stability, the biopharmaceutical industry has the characteristics of high investment and high production standards, and has very high requirements for the technical level and reliability of equipment.
Pharmaceutical machine companies need to combine industry needs to create high-performance, high-reliability Unique equipment can help enterprises to produce high-quality and stable production, thereby reducing costs
.

 　　In terms of automation and intelligence, China's "Made in China 2025" and other strategic deployments have pointed out the direction of automation, intelligence and other transformation and upgrading of the pharmaceutical equipment industry.
The active layout in the manufacturing field will boost the transformation of the pharmaceutical equipment industry from "manufacturing" to "intelligent manufacturing"
.

The industry predicts that the arrival of the era of artificial intelligence will bring about changes in the entire manufacturing industry.
It is expected that by 2025, the application rate of cloudification of Chinese enterprises and the utilization rate of artificial intelligence will reach more than 90%
.

As an important part of the manufacturing industry, the pharmaceutical equipment industry is also expected to usher in high-quality and intelligent development opportunities with the support of a series of policies
.

 　　In addition, energy conservation and environmental protection are the main theme of today's world, and pharmaceutical companies, as high-pollution "big players", are duty-bound
.

The industry pointed out that at present, many pharmaceutical equipment clean fluid process pharmaceutical equipment still has the defects of high energy consumption, large waste discharge, and high production cost.
It is urgent for pharmaceutical machine companies to develop alternative equipment that saves energy and reduces emissions, and has a longer service life of consumables.
Green and sustainable development of pharmaceutical enterprises
.